Advertisement

Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer

      Abstract

      Purpose

      Patients with recurrent and/or metastatic head and neck squamous cell cancer are offered platinum-based chemotherapy plus cetuximab; however, this strategy is not cost-effective. We evaluated the cost-effectiveness of a hypothetical predictive molecular test to identify and treat only patients potentially responsive to cetuximab (C) added to platinum-fluorouracil (PF) (PF + C POS) versus the administration of PF + C to all patients (PF + C ALL).

      Methods

      A Markov model has been developed to estimate health outcomes (quality-adjusted life years [QALYs]; life years [LYs]) and costs of the 2 strategies on a time horizon of 3 years from the Italian health care perspective. For the response to treatment, a definition, including partial or complete response, has been applied. In the base-case scenario, molecular test sensitivity, specificity, and cost have been assumed equal to 85%, 70%, and €4000, respectively.

      Findings

      The model estimated 0.5285 QALYs (0.9245 LYs) and 0.5666 QALYs (0.9949 LYs) for PF + C POS and PF + C ALL, respectively. The incremental cost-utility ratio of PF + C ALL versus PF + C POS was €112,462/QALY, suggesting the administration of PF + C only to patients who would be responsive to it.

      Implications

      The use of cetuximab with chemotherapy could be a cost-effective choice in first-line recurrent and/or metastatic head and neck squamous cell cancer if based on a molecular selection able to identify which patients will achieve partial or complete response to the treatment. The developed model may be usefully applied to new emerging treatments, such as immunotherapeutic agents in the same setting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Xu J.
        • Ward E.
        Cancer statistics, 2010.
        CA Cancer J Clin. 2010; 60: 277-300
        • Argiris A.
        • Karamouzis M.V.
        • Raben D.
        • et al.
        Head and neck cancer.
        Lancet. 2008; 371: 1695-1709
        • Ferlay J.
        • Soerjomataram I.
        • Ervik M.
        • et al.
        GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11.
        International Agency for Research on Cancer, Lyon, France2013
        http://globocan.iarc.fr
        Date accessed: August 8, 2018
        • Gatta G.
        • Botta L.
        • Sánchez M.J.
        • et al.
        Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study.
        Eur J Cancer. 2015; 51: 2130-2143
        • Vermorken J.B.
        • Mesia R.
        • Rivera F.
        • et al.
        Platinum-based chemotherapy plus cetuximab in head and neck cancer.
        N Engl J Med. 2008; 359: 1116-1127
        • Bagust A.
        • Greenhalgh J.
        • Boland A.
        • et al.
        Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
        Pharmacoeconomics. 2010; 28: 439-448
        • Hannouf M.B.
        • Sehgal C.
        • Cao J.Q.
        • et al.
        Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.
        PLoS One. 2012; 7e38557
        • Olsen D.
        • Jørgensen J.T.
        Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
        Front Oncol. 2014; 4: 105
        • FDA
        The Draft Concept Paper on Drug-Diagnostic Co-development.
        US Food and Drug Administration, Rockville, MD2005
        • Mittmann N.
        • Au H.J.
        • Tu D.
        • et al.
        Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
        J Natl Cancer Inst. 2009; 101: 1182-1192
        • Licitra L.
        • Mesia R.
        • Rivera F.
        • et al.
        Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
        Ann Oncol. 2011; 22: 1078-1087
        • Licitra L.
        • Störkel S.
        • Kerr K.M.
        • et al.
        Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
        Eur J Cancer. 2013; 49: 1161-1168
        • Chung C.H.
        • Seeley E.H.
        • Roder H.
        • et al.
        Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
        Cancer Epidemiol Biomarkers Prev. 2010; 19: 358-365
        • Bossi P.
        • Bergamini C.
        • Siano M.
        • et al.
        Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab.
        Clin Cancer Res. 2016; 22: 3961-3970
        • Buyse M.
        • Loi S.
        • van’t V.L.
        • et al.
        Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
        J Natl Cancer Inst. 2006; 98: 1183-1192
      1. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?.
        Genet Med. 2009; 11: 66-73
        • Holmström B.
        • Johansson M.
        • Bergh A.
        • et al.
        Prostate specific antigen for early detection of prostate cancer: longitudinal study.
        BMJ. 2009; 339: b3537
        • Markopoulos C.
        Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
        Expert Rev Anticancer Ther. 2013; 13: 179-194
        • Slodkowska E.A.
        • Ross J.S.
        MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.
        Expert Rev Mol Diagn. 2009; 9: 417-422
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Colevas D.A.
        Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
        J Clin Oncol. 2006; 24: 2644-2652
        • Argiris A.
        • Li Y.
        • Forastiere A.
        Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
        Cancer. 2004; 101: 2222-2229
        • Sonnenberg F.A.
        • Beck J.R.
        Markov models in medical decision making: a practical guide.
        Med Decis Making. 1993; 13: 322-338
      2. TreeAge Pro. TreeAge Software, Inc. Williamstown, MA; https://www.treeage.com. Accessed October 11, 2019.

        • ERG Report
        Cetuximab for Recurrent And/or Metastatic Head and Neck Cancer.
        NICE STA, 2008
        • National Institute for Health and Clinical Excellence (NICE)
        Guide to the Methods of Technology Appraisal.
        2013
        • Marseille E.
        • Larson B.
        • Kazi D.S.
        • Kahn J.G.
        • Rosen S.
        Thresholds for the cost-effectiveness of interventions: alternative approaches.
        Bull World Health Organ. 2015; 93: 118-124
        • Yabroff K.R.
        • Davis W.W.
        • Lamont E.B.
        • et al.
        Patient time costs associated with cancer care.
        J Natl Cancer Inst. 2007; 99: 14-23
      3. Baldini M. Dieci anni bui per le famiglie italiane. https://www.lavoce.info/archives/18744/giovani-lavoro-crisi-reddito. Accessed October 11, 2019.

        • Constenla D.O.
        • Hill M.E.
        • A'Hern R.P.
        • et al.
        Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck.
        Ann Oncol. 1997; 8: 445-449
        • Guntinas-Lichius O.
        • Rühlow S.
        • Veelken F.
        • et al.
        Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
        J Cancer Res Clin Oncol. 2009; 135: 901-908
        • Schnipper L.E.
        • Davidson N.E.
        • Wollins D.S.
        • et al.
        American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options.
        J Clin Oncol. 2015; 33: 2563-2577
        • Levy A.
        • Blanchard P.
        • Bellefqih S.
        • et al.
        Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
        Anticancer Drugs. 2014; 25: 1220-1226
        • Descamps G.
        • Karaca Y.
        • Lechien J.R.
        • et al.
        Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
        J Cancer Res Clin Oncol. 2016; 142: 2185-2196
        • Vermorken J.B.
        • Psyrri A.
        • Mesia R.
        • et al.
        Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
        Ann Oncol. 2014; 25: 801-807
        • Mesía R.
        • Rivera F.
        • Kawecki A.
        • et al.
        Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
        Ann Oncol. 2010; 21: 1967-1973
        • Swedish Council on Health Technology Assessment
        Methods for health economic evaluations. A guideline based on current practices in Europe.
        May 2015
        • Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971]
        Appraisal Consultation Document.